Skip to main content

Tripos, Continuing Reorganization, Sells Four UK Buildings

NEW YORK (GenomeWeb News) — Tripos has sold four buildings at its Bude, UK, Discovery Research location to real estate investors and Park Research, a local chemistry company, according to a Securities and Exchange Commission filing last week.
 
The move, part of Tripos’ plan to sell its chemical research units, enabled the company to recognize around $1.3 million in gross proceeds.
 
On Nov. 14 Tripos said it was “engaged in advanced discussions” for the sale of the entire Discovery Research division, of which the UK facilities were a part.
 
The company is currently trying to become a privately held entity that will focus exclusively on developing and marketing its software and informatics business, which was bought by Vector Capital on Nov. 20 for $26.5 million in cash.
 
As part of Vector, the informatics business will continue to operate under the Tripos name, will remain in St. Louis, and will retain much of the same informatics and software research staff.

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.